Why Tandem Diabetes Care (TNDM) Is Up 14.3% After FDA Clears Android App for Mobi System and What’s Next
November 22, 2025
Tandem Diabetes Care has recently achieved a significant milestone with the U.S. Food and Drug Administration’s clearance of the Android version of the Tandem Mobi mobile app. This development is poised for a limited release in December 2025, followed by broader commercial availability in early 2026. The clearance not only enhances the accessibility of Tandem’s automated insulin delivery system but also allows users to manage their diabetes directly from compatible Android smartphones, thereby expanding the potential user base.
Tandem Diabetes Care Investment Narrative Recap
Investors in Tandem Diabetes Care must have confidence in the company’s ability to foster consistent adoption of its insulin delivery technology within a competitive and rapidly evolving landscape. The recent FDA clearance for the Android version of the Tandem Mobi app is expected to positively influence customer adoption rates and serve as a catalyst for near-term growth by broadening accessibility. However, challenges remain, particularly in execution and competition. A critical concern is whether new user growth can surpass the anticipated stagnation in renewal rates in 2026.
Adding to this narrative is the upcoming launch in October 2025 of the t:slim X2’s integration with Abbott’s FreeStyle Libre 3 Plus CGM sensor. This expanded compatibility aims to draw more continuous glucose monitoring (CGM) users into Tandem’s ecosystem, potentially enhancing both new pump initiations and high-margin recurring supply revenue.
While the prospects for increased device integration and Android compatibility may drive new user adoption, they do not entirely mitigate the risks associated with a possible slowdown in renewals. Analysts project that Tandem Diabetes Care could reach .2 billion in revenue and .4 million in earnings by 2028, assuming an annual revenue growth rate of 7.5% and an earnings increase of 9.9 million from its current earnings of -5.5 million. This outlook yields a fair value estimate of .64 per share, indicating a 3% downside from its current market price.
Exploring Other Perspectives
TNDM Community Fair Values as at Nov 2025
The Simply Wall St Community presents a range of fair value forecasts for Tandem Diabetes Care, spanning from US.64 to US.57 per share. Despite this variance, the pressing question remains whether the expanded mobile access will sufficiently counterbalance the risk of declining renewals in 2026. Market participants exhibit differing opinions on the intersection of value and risk.
Build Your Own Tandem Diabetes Care Narrative
For those who disagree with prevailing narratives, there is an opportunity to craft a personalized investment story in just under three minutes. Exceptional investment returns often arise from independent thinking rather than following the crowd.
Interested In Other Possibilities?
Time is of the essence. There are free picks currently gaining traction that you may want to explore before they become widely recognized.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using an unbiased methodology. Our articles are not intended as financial advice. They do not constitute a recommendation to buy or sell any stock, nor do they take into account your individual objectives or financial situation. Our aim is to deliver long-term focused analysis driven by fundamental data. Please note that our analysis may not incorporate the latest price-sensitive company announcements or qualitative material. Simply Wall St holds no positions in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover whether Tandem Diabetes Care might be undervalued or overvalued through our detailed analysis, which includes fair value estimates, potential risks, dividends, insider trades, and its financial condition. Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Why Tandem Diabetes Care (TNDM) Is Up 14.3% After FDA Clears Android App for Mobi System and What’s Next
Tandem Diabetes Care has recently achieved a significant milestone with the U.S. Food and Drug Administration’s clearance of the Android version of the Tandem Mobi mobile app. This development is poised for a limited release in December 2025, followed by broader commercial availability in early 2026. The clearance not only enhances the accessibility of Tandem’s automated insulin delivery system but also allows users to manage their diabetes directly from compatible Android smartphones, thereby expanding the potential user base.
Tandem Diabetes Care Investment Narrative Recap
Investors in Tandem Diabetes Care must have confidence in the company’s ability to foster consistent adoption of its insulin delivery technology within a competitive and rapidly evolving landscape. The recent FDA clearance for the Android version of the Tandem Mobi app is expected to positively influence customer adoption rates and serve as a catalyst for near-term growth by broadening accessibility. However, challenges remain, particularly in execution and competition. A critical concern is whether new user growth can surpass the anticipated stagnation in renewal rates in 2026.
Adding to this narrative is the upcoming launch in October 2025 of the t:slim X2’s integration with Abbott’s FreeStyle Libre 3 Plus CGM sensor. This expanded compatibility aims to draw more continuous glucose monitoring (CGM) users into Tandem’s ecosystem, potentially enhancing both new pump initiations and high-margin recurring supply revenue.
While the prospects for increased device integration and Android compatibility may drive new user adoption, they do not entirely mitigate the risks associated with a possible slowdown in renewals. Analysts project that Tandem Diabetes Care could reach .2 billion in revenue and .4 million in earnings by 2028, assuming an annual revenue growth rate of 7.5% and an earnings increase of 9.9 million from its current earnings of -5.5 million. This outlook yields a fair value estimate of .64 per share, indicating a 3% downside from its current market price.
Exploring Other Perspectives
The Simply Wall St Community presents a range of fair value forecasts for Tandem Diabetes Care, spanning from US.64 to US.57 per share. Despite this variance, the pressing question remains whether the expanded mobile access will sufficiently counterbalance the risk of declining renewals in 2026. Market participants exhibit differing opinions on the intersection of value and risk.
Build Your Own Tandem Diabetes Care Narrative
For those who disagree with prevailing narratives, there is an opportunity to craft a personalized investment story in just under three minutes. Exceptional investment returns often arise from independent thinking rather than following the crowd.
Interested In Other Possibilities?
Time is of the essence. There are free picks currently gaining traction that you may want to explore before they become widely recognized.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using an unbiased methodology. Our articles are not intended as financial advice. They do not constitute a recommendation to buy or sell any stock, nor do they take into account your individual objectives or financial situation. Our aim is to deliver long-term focused analysis driven by fundamental data. Please note that our analysis may not incorporate the latest price-sensitive company announcements or qualitative material. Simply Wall St holds no positions in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover whether Tandem Diabetes Care might be undervalued or overvalued through our detailed analysis, which includes fair value estimates, potential risks, dividends, insider trades, and its financial condition. Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Alternatively, email editorial-team@simplywallst.com